Mutlu Acar

Mutlu Acar

Auto-generated profile, based on publicly available information

Mutlu Acar

Department of Ophthalmology, Yuksek Ihtisas University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2012 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
MAMutlu Acar
Mutlu Acar
HFHikmet FIRAT
Hikmet FIRAT
UAUgur Acar
Ugur Acar
SASadik Ardic
Sadik Ardic

1 April 2014 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
MAMutlu Acar
Mutlu Acar
HFHikmet FIRAT
Hikmet FIRAT
MYMelike Yuceege
Melike Yuceege
SASadik Ardıc
Sadik Ardıc

10 February 2016 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
ÖBÖmer Bayır
Ömer Bayır
MAMutlu Acar
Mutlu Acar
EYElvan Yüksel
Elvan Yüksel
MYMelike Yüceege
Melike Yüceege
GSGüleser Saylam
Güleser Saylam
MKMehmet Hakan Korkmaz
Mehmet Hakan Korkmaz

26 December 2016 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
ADAysun Sanal Dogan
Aysun Sanal Dogan
MAMutlu Acar
Mutlu Acar
MKMustafa Kosker
Mustafa Kosker
NANese Arslan
Nese Arslan
CGCanan Gurdal
Canan Gurdal

1 January 2025 in Arquivos Brasileiros de Oftalmologia
Verified
Journal Article
Open access
ABAlperen Bahar
Alperen Bahar
HSHuri Sabur
Huri Sabur
MAMutlu Acar
Mutlu Acar
This study was conducted to investigate the effect of injectable platelet-rich fibrin on the recovery of compromised epithelium due to crosslinking treatment. In this comparative study, the epithelial closure rates and in vivo confocal biomicroscopy results of 26 patients with keratoconus who underwent subconjunctival injection of injectable platelet-rich fibrin near the limbus after epithelium-off corneal crosslinking treatment were compared with those of 25 patients who did not receive the injection of injectable platelet-rich fibrin. The average time to epithelial defect closure in the injectable platelet-rich fibrin group was 2.76 ± 0.90 days compared to 3.56 ± 0.86 days in the non-injectable platelet-rich fibrin group (p=0.003). At the end of the 1st month, the mean subbasal nerve plexus density was 1.26 ± 1.61 nerves/mm2 in the injectable platelet-rich fibrin group, whereas it was 0.72 ± 0.89 nerves/mm2 in the non-injectable platelet-rich fibrin group (p=0.016). By the 3rd month, the density increased to 3.42 ± 1.13 nerves/mm2 in the injectable platelet-rich fibrin group and 2.36 ± 1.15 nerves/mm2 in the non-injectable platelet-rich fibrin group (p=0.002). Similarly, the anterior stromal keratocyte density at the end of the 1st month was 93.6 ± 33.5 cells/mm2 in the injectable platelet-rich fibrin group compared to 67.3 ± 26.4 cells/mm2 in the non-injectable platelet-rich fibrin group (p=0.001). By the end of the 3rd month, the density increased to 255.2 ± 45.7 cells/mm2 in the injectable platelet-rich fibrin group and 222.1 ± 43.6 cells/mm2 in the non-injectable platelet-rich fibrin group (p=0.011). In the non-injectable platelet-rich fibrin group, one patient developed a sterile infiltrate at the end of the 1st week, whereas no complications were observed in the injectable platelet--rich fibrin group. Subconjunctival injectable platelet-rich fibrin application is an effective and safe method for corneal epithelial healing after crosslinking treatment.

3 July 2015 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CECan Ergin
Can Ergin
MAMutlu Acar
Mutlu Acar
HAHavva Kaya Akış
Havva Kaya Akış
MGMüzeyyen Gönül
Müzeyyen Gönül
CGCanan Gürdal
Canan Gürdal